The drug Lamisil® is generally well tolerated. Side effects are usually mild or moderate and are transient. The following are undesirable phenomena that have been observed during clinical trials or at post-registration period.
When assessing the incidence of side effects, the following grades are used: "very often" (≥1 / 100 <1/100), "infrequently" (≥1 / 1000 <1/100), "infrequently" (≥1 / 10000 <1/1000), " very rare "(<1/10000), including individual messages.
Violations of the blood and lymphatic system: infrequently, anemia; very rarely - neutropenia, agranulocytosis, pancytopenia, thrombocytopenia.
Immune system disorders: very rarely - anaphylactoid reactions (including angioedema), cutaneous and systemic lupus erythematosus (or their exacerbation).
Disorders of the psyche: often - depression; infrequent anxiety.
Disturbances from the nervous system: very often - headache; often - dizziness, taste disorders sensations, until their loss (usually recovery occurs within several weeks after discontinuation treatment). There are separate reports on cases of prolonged disorders of taste sensations. In some cases, against the background intake was noted depletion. Infrequently: paresthesia, hypoesthesia.
Disturbances on the part of the organ of sight: infrequently - impaired vision.
Violations from the organ of hearing and labyrinthine disorders: infrequent - noise in the ears.
Disorders from the liver and bile ducts: rarely hepatobiliary dysfunction (predominantly cholestatic nature), incl. hepatic insufficiency, including very rare cases of severe hepatic insufficiency (some with a fatal outcome or requiring liver transplantation, in most cases,when hepatic insufficiency developed, patients had serious accompanying systemic disease and the cause-and-effect relationship of liver failure with the drug Lamisil® was doubtful), hepatitis, jaundice, cholestasis, increased activity of "liver" enzymes.
Disorders from the digestive system: very often - bloating, decreased appetite, indigestion, nausea, mild abdominal pain, diarrhea.
Disturbances from the skin and subcutaneous tissues: very often - a rash, hives; infrequently - photosensitivity reactions; very rarely - Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, multiform erythema, toxic skin rash, exfoliative dermatitis, bullous dermatitis, psoriasis-like rashes on the skin or exacerbation of psoriasis, alopecia.
Disturbances from musculoskeletal and connective tissue: very often - arthralgia, myalgia.
General disorders: often - feeling fatigue; infrequent - an increase in body temperature.
Laboratory and instrumental data: infrequently - weight loss (secondary to the violation of taste sensations).
Based on spontaneous reports, received during the post-registration period, and literary data are revealed the following undesirable phenomena, frequency due to an inaccurate amount patients can not be established:
Immune system disorders: anaphylactic reactions, syndrome similar to serum sickness.
Disturbances on the part of the organ of sight: blurred vision, reduced visual acuity.
Disturbances from the skin and subcutaneous fabrics: rash with eosinophilia and systemic symptoms (rash, swelling, fever and enlargement of lymph nodes).
Violations from the organ of hearing and labyrinthine disorders: hearing loss, hearing impairment.
Vascular disorders: vasculitis.
Disturbances from the nervous system: loss of smell, including long-term period of time, decrease in olfaction.
Disorders from the digestive system systems: pancreatitis.
Disturbances from the musculoskeletal and connective tissue: rhabdomyolysis.
General disorders: influenza-like syndrome.
Laboratory and instrumental data: increased activity of creatine phosphokinase in the blood serum.
If any of the instructions specified in the instruction side effects are aggravated, or you noticed any other side effects not specified in the instructions, report this doctor.